

Docket No. 215869US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Nobuya MATSUOKA, et al.

SERIAL NO: 09/926,641

GAU:

FILED: November 28, 2001

EXAMINER:

FOR: AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF SYNAPTIC TRANSMISSION COMPRISING COMPOUND HAVING BRAIN SOMATOSTATIN ACTIVATION PROPERTY

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☒ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Surinder Sachar

Registration No. 34,423



22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 10/01)

LIST OF RELATED CASES

<u>Docket Number</u>	<u>Serial or Patent No.</u>	<u>Filing or Issue Date</u>	<u>Status or Patentee</u>
0018-1058-0	6,344,358	02/05/02	MATSUOKA, et al.
217312US0 DIV	10/041,592	01/10/02	PENDING
215869US0 PCT*	09/926,641	11/28/01	PENDING

COPY

*Present application; listed for information.

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 215869US0PCT		SERIAL NO. 09/926,641	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Nobuya MATSUOKA, et al.			
				FILING DATE November 28, 2001		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
✓	AO	98 25914 ✓	06/18/98	WO			No
✓	AP	00 42011 ✓	07/20/00	WO			No
✓	AQ	98 35951 ✓	08/20/98	WO			No
✓	AR	0 436 734 ✓	07/17/91	EP			No
✓	AS	97 36871 ✓	10/09/97	WO			No
✓	AT	99 55674 ✓	11/04/99	WO			No
	AU						
	AV						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
✓	AW	Nobuya MATSUOKA et al.: "FK960 'N-(4-acetyl-1-piperazinyl)-p-fluorobenzam antideementia drug, improves visual recognition memory in rhesus monkeys: comparison with physostigmine" J. PHARMACOL. EXP. THER., 280(3), pages 1201-1209 1997 ✓					
✓	AX	A. GRAUL et al.: "FK-960. Cognition enhancer." DRUGS FUTURE, 22(8), pages 830-832 1997 ✓					
✓	AY	Nobuya MATSUOKA et al.: "FK960, a novel potential anti-dementia drug, augments long-term potentiation in mossy fiber-CA3 pathway of guinea-pig hippocampal slices" BRAIN RESEARCH, vol. 794, no. 2, pages 248-254 06/01/98 ✓					
	AZ					<input type="checkbox"/> Additional References sheet(s) attached	
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							


OSMM&N File No. 215869US0PCT
Serial No. 09/926,641

Dept.: NFO/smp FF
Due Date: 02/28/02

In the matter of the Application of: Nobuya MATSUOKA et al.
For: AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF
SYNAPTIC TRANSMISSION COMPRISING COMPOUND HAVING BRAIN
SOMATOSTATIN ACTIVATION PROPERTY

The following has been received in the U.S. Patent Office on the date stamped hereon:

- | | |
|---|---|
| <input type="checkbox"/> Combined Declaration, Petition & Power of Attorney | <input checked="" type="checkbox"/> Dep. Acct. Order Form |
| <input type="checkbox"/> Check for | |
| <input type="checkbox"/> Assignment/PTO 1595 pages: | |
| <input checked="" type="checkbox"/> Information Disclosure Statement | <input checked="" type="checkbox"/> PTO-1449 |
| <input checked="" type="checkbox"/> Cited References (2) | |
| <input checked="" type="checkbox"/> International Search Report | |
| <input type="checkbox"/> Statement of Relevancy | <input type="checkbox"/> Cited Pending Applications |
| <input checked="" type="checkbox"/> List of Related Cases | |
| <input type="checkbox"/> Petition for Extension of Time | |
| <input type="checkbox"/> Small Entity Status is claimed | |
| <input type="checkbox"/> | |
| <input type="checkbox"/> | |



COPY

Received: _____